[Congressional Record Volume 147, Number 159 (Friday, November 16, 2001)]
[Senate]
[Pages S12015-S12016]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




   HEMATOLOGICAL CANCER RESEARCH INVESTMENT AND EDUCATION ACT OF 2001

  Mr. REID. Mr. President, I ask unanimous consent that the Senate 
proceed to the immediate consideration of Calendar No. 221, S. 1094.
  The PRESIDING OFFICER. The clerk will report the bill by title.
  The assistant legislative clerk read as follows:

       A bill (S. 1094) to amend the Public Health Service Act to 
     provide for research, information, and education with respect 
     to blood cancer.

  There being no objection, the Senate proceeded to consider the 
bill which had been reported from the Committee on Health, Education, 
Labor, and Pensions, with an amendment to strike all after the enacting 
clause and insert in lieu thereof the following:

     SECTION 1. SHORT TITLE.

       This Act may be cited as the ``Hematological Cancer 
     Research Investment and Education Act of 2001''.

     SEC. 2. FINDINGS.

       Congress finds that:
       (1) An estimated 109,500 people in the United States will 
     be diagnosed with leukemia, lymphoma, and multiple myeloma in 
     2001.
       (2) New cases of the blood cancers described in paragraph 
     (1) account for 8.6 percent of new cancer cases.
       (3) Those devastating blood cancers will cause the deaths 
     of an estimated 60,300 persons in the United States in 2001. 
     Every 9 minutes, a person in the United States dies from 
     leukemia, lymphoma, or multiple myeloma.
       (4) While less than 5 percent of Federal funds for cancer 
     research are spent on those blood cancers, those blood 
     cancers cause 11 percent of all cancer deaths in the United 
     States.
       (5) Increased Federal support of research into leukemia, 
     lymphoma, and multiple myeloma has resulted and will continue 
     to result in significant advances in the treatment, and 
     ultimately the cure, of those blood cancers as well as other 
     cancers.

     SEC. 3. RESEARCH, INFORMATION, AND EDUCATION WITH RESPECT TO 
                   BLOOD CANCER.

       Part C of title IV of the Public Health Service Act (42 
     U.S.C. 285 et seq.) is amended by inserting after section 
     419C the following:

     ``SEC. 417D. RESEARCH, INFORMATION, AND EDUCATION WITH 
                   RESPECT TO BLOOD CANCER.

       ``(a) Joe Moakley Research Excellence Program.--
       ``(1) In general.--The Director of NIH shall expand, 
     intensify, and coordinate programs for the conduct and 
     support of research with respect to blood cancer, and 
     particularly with respect to leukemia, lymphoma, and multiple 
     myeloma.
       ``(2) Administration.--The Director of NIH shall carry out 
     this subsection through the Director of the National Cancer 
     Institute and in collaboration with any other agencies that 
     the Director determines to be appropriate.
       ``(3) Authorization of appropriations.--For the purpose of 
     carrying out this subsection, there is authorized to be 
     appropriated such sums as may be necessary for fiscal year 
     2002 and each subsequent fiscal year. Such authorizations of 
     appropriations are in addition to other authorizations of 
     appropriations that are available for such purpose.
       ``(b) Geraldine Ferraro Cancer Education Program.--
       ``(1) In general.--The Secretary shall direct the 
     appropriate agency within the Department of Health and Human 
     Services, in collaboration with the Director of NIH, to 
     establish and carry out a program to provide information and 
     education for patients and the general public with respect to 
     blood cancer, and particularly with respect to the treatment 
     of leukemia, lymphoma, and multiple myeloma.
       ``(2) Administration.--The Agency determined by the 
     Secretary under paragraph (1) shall carry out this subsection 
     in collaboration with private health organizations that have 
     national education and patient assistance programs on blood-
     related cancers.
       ``(3) Authorization of appropriations.--For the purpose of 
     carrying out this subsection, there is authorized to be 
     appropriated such sums as may be necessary for fiscal year 
     2002 and each subsequent fiscal year. Such authorizations of 
     appropriations are in addition to other authorizations of 
     appropriations that are available for such purpose.''.

  Mr. REID. Mr. President, I ask unanimous consent that the committee 
substitute be agreed to, the bill be read a third time and passed, the 
motion to reconsider be laid upon the table, and that any statements 
relating thereto be printed in the Record with no intervening action or 
debate.
  The PRESIDING OFFICER. Without objection, it is so ordered.
  The committee amendment in the nature of a substitute was agreed to.
  The bill (S. 1094), as amended, was read a third time, and passed, as 
follows:

                                S. 1094

       Be it enacted by the Senate and House of Representatives of 
     the United States of America in Congress assembled,

     SECTION 1. SHORT TITLE.

       This Act may be cited as the ``Hematological Cancer 
     Research Investment and Education Act of 2001''.

     SEC. 2. FINDINGS.

       Congress finds that:
       (1) An estimated 109,500 people in the United States will 
     be diagnosed with leukemia, lymphoma, and multiple myeloma in 
     2001.
       (2) New cases of the blood cancers described in paragraph 
     (1) account for 8.6 percent of new cancer cases.
       (3) Those devastating blood cancers will cause the deaths 
     of an estimated 60,300 persons in the United States in 2001. 
     Every 9 minutes, a person in the United States dies from 
     leukemia, lymphoma, or multiple myeloma.
       (4) While less than 5 percent of Federal funds for cancer 
     research are spent on those blood cancers, those blood 
     cancers cause 11 percent of all cancer deaths in the United 
     States.
       (5) Increased Federal support of research into leukemia, 
     lymphoma, and multiple myeloma has resulted and will continue 
     to result in significant advances in the treatment, and 
     ultimately the cure, of those blood cancers as well as other 
     cancers.

     SEC. 3. RESEARCH, INFORMATION, AND EDUCATION WITH RESPECT TO 
                   BLOOD CANCER.

       Part C of title IV of the Public Health Service Act (42 
     U.S.C. 285 et seq.) is amended by inserting after section 
     419C the following:

     ``SEC. 417D. RESEARCH, INFORMATION, AND EDUCATION WITH 
                   RESPECT TO BLOOD CANCER.

       ``(a) Joe Moakley Research Excellence Program.--
       ``(1) In general.--The Director of NIH shall expand, 
     intensify, and coordinate programs for the conduct and 
     support of research with respect to blood cancer, and 
     particularly with respect to leukemia, lymphoma, and multiple 
     myeloma.
       ``(2) Administration.--The Director of NIH shall carry out 
     this subsection through the Director of the National Cancer 
     Institute and in collaboration with any other agencies that 
     the Director determines to be appropriate.
       ``(3) Authorization of appropriations.--For the purpose of 
     carrying out this subsection, there is authorized to be 
     appropriated such sums as may be necessary for fiscal year 
     2002 and each subsequent fiscal year. Such authorizations of 
     appropriations are in addition to other authorizations of 
     appropriations that are available for such purpose.
       ``(b) Geraldine Ferraro Cancer Education Program.--
       ``(1) In general.--The Secretary shall direct the 
     appropriate agency within the Department of Health and Human 
     Services, in collaboration with the Director of NIH, to 
     establish and carry out a program to provide information and 
     education for patients and the general public with respect to 
     blood cancer, and particularly with respect to the treatment 
     of leukemia, lymphoma, and multiple myeloma.
       ``(2) Administration.--The Agency determined by the 
     Secretary under paragraph (1) shall carry out this subsection 
     in collaboration with private health organizations that have 
     national education and patient assistance programs on blood-
     related cancers.
       ``(3) Authorization of appropriations.--For the purpose of 
     carrying out this subsection, there is authorized to be 
     appropriated such sums as may be necessary for

[[Page S12016]]

     fiscal year 2002 and each subsequent fiscal year. Such 
     authorizations of appropriations are in addition to other 
     authorizations of appropriations that are available for such 
     purpose.''.

                          ____________________